Dnalite Therapeutics, Inc.
San Francisco, CA · CIK 0001922565 · Biotech · Private
Oral lipid nanoparticle delivery platform for systemic protein expression and gene therapy
particella.bio →- Grants
- $1.4M
- 2 awards
- Sector median: 1
- Raised
- $5.6M
- 1 Form D · Apr 2022
- 54 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 17
- 0 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Development Of An Orally Administered Gene Delivery Platform For Induced Protein Secretion Via The Gastrointestinal Tract | $224,684 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II:Development Of An Orally Administered Gene Therapy For Granulocyte Colony-Stimulating Factor | $1,160,802 | |
| Private capital raised | Form D · SEC | $5,596,650 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1174 | ISOThrive Inc. | — | $17M |
| 1175 | Unleash Immuno Oncolytics, Inc. | — | $3.0M |
| 1176 | Cessation Therapeutics, Inc. | — | $6.8M |
| 1177 | Dnalite Therapeutics, Inc. | — | $5.6M |
| 1178 | Xenon Pharmaceuticals | — | — |
| 1179 | Pagari Life Science Corp. | — | $678K |
| 1180 | PRIMAL THERAPIES, INC. | — | $677K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mubhij AhmadDirector · Executive Officer
- Timothy DayDirector
- Drew LanzaDirector
- Andrew McClaryDirector
- David RabukaDirector
Patents
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Mucus-penetrating Peptides, Delivery Vehicles And Methods Of Therapyapplication
- Structures And Methods For Gene Therapyapplication
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Compositions And Methods For Biological Delivery Vehiclesapplication
- Bile Salt Stable Delivery Vehiclesapplication
- Mucus-penetrating Peptides, Delivery Vehicles And Methods Of Therapyapplication
- Mucus-penetrating Peptides, Delivery Vehicles And Methods Of Therapyapplication
- Structures And Methods For Gene Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.